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Abstract 
Exploiting the potential of bacteriophages for phage therapy is an exciting future 
prospect. However, in order to be successful, there is a pressing need for the 
manufacture of safe and efficacious phage drug products to treat patients. 
Scalable manufacture of phage biologics as a stable solid dry powder form is 
highly desirable and achievable using the process of spray drying. Spray drying of 
purified phage suspensions formulated with suitable excipients can be carried out 
in a single step with high process throughput and at relatively low cost. The 
resulting phage-containing powders can possess good storage shelf-life. The 
process allows control over the final phage dose in the powder and production of 
microparticles suitable for a variety of therapeutic uses. Spray dried powders may 
include different polymer formulations employing a multitude of different triggers 
for phage release at the target site including pH, enzymes, virulence factors etc. 
The activity of the phages in spray dried powders is adversely affected during 
spray drying due to dessication and thermal stresses which need to be controlled. 
The choice of polymers, excipients and moisture content of the dry powders 
affects the material glass transition temperature and the stability of the phages 
during storage. The storage temperature and storage humidty are important 
factors affecting the stability of the phages in the dry powders. A quality by design 
(QbD) approach for phage drug product development needs to identify drug 
product characteristics that are critical to quality from the patient's perspective 
and translates them into the critical quality attributes (CQA) of the drug product. 
The relationship between the phage drug product CQAs and formulation 
development and spray drying process conditions are discussed in this article. 
Introduction 
Phage drug products need careful formulation development and an appreciation 
of the chemical and physical stresses that bacteriophages may encounter both 
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during processing as well as during storage once formulated needs early 
consideration. Phage inactivation and long-term reduction in phage titres upon 
storage is highly undesirable. Delivery of high titres of phages and their controlled 
release at the site of treatment affects phage pharmacokinetics (Malik et al., 
2017). The physical and chemical properties of the materials used in the 
formulation need careful consideration when selecting a technique for 
encapsulation. Many techniques and processes may be used for stabilising, 
immobilising and encapsulating phages including spray-drying, spray freeze 
drying, freeze drying, extrusion dripping methods, emulsion and polymerisation 
techniques (Malik et al., 2017). Phages are protein structures and they are 
therefore susceptible to factors known to denature proteins; these include 
exposure to organic solvents (Lee and Belcher, 2004; Puapermpoonsiri et al., 
2009), high temperatures (Briers et al., 2008), pH (Briers et al., 2008; Knezevic et 
al., 2011), ionic strength (Knezevic et al., 2011) and interfacial effects. Additionally, 
mechanical stresses during formulation or encapsulation including shear stresses 
during mixing and agitation, atomisation during spraying (Leung et al., 2016) and, 
desiccation stresses during drying (Dini and de Urraza, 2013), need careful 
consideration. Scalable low-cost processes that are compliant with current Good 
Manufacturing Practices (cGMP) are needed for phage encapsulation. 
Spray Drying of Bacteriophages 
Spray drying processes atomise a liquid containing dissolved solids, converting it 
into a fine mist or aerosol which is contacted with a hot dry gas (typically hot dry 
air) inside a drying chamber (Figure 1). Due to the high surface area to volume 
ratio of the very small atomised droplets (droplet size typically 10 - 100 µm), the 
solvent rapidly evaporates with each droplet forming a particle comprising the 
non-volatile components (solids fraction in feed containing bacteriophage and 
excipients) along with a small amount of residual moisture. The particles are 
separated from the airstream exiting the dryer, and cyclones or bag filters are 
typically used for this. Spray drying is a scalable industrial process technology 
and is widely used to produce fine powders containing biologicals for 
pharmaceutical applications including pulmonary delivery via dry powder inhalers 
(DPI) (Hoe et al., 2014) (Figure 2). Dry powders are increasingly being 
considered for phage drug products because they show relatively long storage 
stability without requiring a cold supply chain and refrigeration (Carrigy et al., 
2019; Chew and Chan, 2002; Klingler et al., 2009). Spray drying of phages using 
formulations containing synthetic polymers may allow in a single step their 
encapsulation whilst incorporating targeted delivery and controlled release 
aspects such as triggered release in response to pH changes e.g. for 
gastrointestinal delivery (Vinner et al., 2019). The powders may also be filled into 
capsules or compressed into oral solid dosage tablets for ease of administration 
and compliance by patients (Vinner et al., 2019). 
Spray drying of phage biologicals using a Quality-by-Design approach 
Quality-by-design is a concept pioneered by Joseph Juran and is based around 
the concept that quality should be designed into a product rather than relying on 
end-of-pipe testing (Juran, 2008). A high-quality phage drug product needs to be 
safe and efficacious, delivering the therapeutic benefit promised to the consumer 
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on the product label. Regulators such as the US Food and Drug administration 
(US FDA) encourage manufacturers to adopt a risk-based approach using QbD 
principles for drug product development, manufacturing and regulation (Yu et al., 
2014). A QbD-led approach emphasises a deep understanding of the 
manufacturing process and linking product quality to the desired clinical 
performance of the drug product. Designing a robust formulation and 
manufacturing process for phage drug products that consistently delivers the 
desired product quality is essential for the future of phage therapy. Performance-
based quality specifications are critical in ensuring this is achieved. Improved 
product and process understanding helps in designing control strategies to 
ensure the drug product quality remains within acceptable limits without 
compromising safety and efficacy. Spray drying of phage biologicals requires 
identification of process and product characteristics that are critical to product 
quality from the patient's perspective. These then need to be translated into 
critical quality attributes (CQAs) of the phage drug product. Linking formulation 
and manufacturing aspects to CQAs is vital in ensuring the phage drug product 
meets performance quality criteria. This requires defining what the phage 
biological's quality target product profile (QTPP) looks like and linking it to CQAs. 
Identification of critical material attributes (CMAs) (explained below) that are 
relevant to spray drying of phage biologicals needs to be ascertained as well as 
critical process parameters (CPPs) specific for the spray drying process. 
Implementation of process control strategies and accounting for variability in 
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Figure 1. Schematic diagram illustrating a typical spray drying set-up to produce phage powders. 
 
Figure 2. Scanning Electron Microscopy (SEM) images of spray dried phage-containing powders dried 
at an outlet temperature of 80°C using a bench-top spray dryer employing a 2-fluid nozzle for liquid 
Figure 1. Schematic diagram illustrating a typical spray drying set-up to produce phage powders.
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process inputs as well as putting specifications on CMAs and the drug substance, 
excipients and drug products is needed (Yu et al., 2014). 
The QTPP of the phage drug product is the basis for the phage drug product 
development and is a summary of all the quality attributes that the drug product 
needs to meet to ensure it is safe and efficacious (Yu et al., 2014). Identification of 
the phage drug product's CQAs is the next step and includes many attributes 
including phage titre in the powder, the powder moisture content, the material's 
glass transition temperature etc (see summary Table 1). The QTPP of new phage 
drug products needs to be adequately defined before drug product development 
work commences. A focus on the phage product design is just as important a 
consideration as that of process design. The stability of the phage drug product 
throughout its shelf life needs to be confirmed through stability studies. The key 
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Figure 2. Scanning Electron Microscopy (SEM) images of spray dried phage-containing powders dried at an 
outlet temperature of 80°C using a bench-top spray dryer employing a 2-fluid nozzle for liquid atomisation. The 
arrow and circle indicate embedded myoviridae phage particles in the core-shell structure of the microparticles.
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objective of product design is to ensure that the phage drug product retains the 
desired QTPP over the product shelf life (Yu et al., 2014). Failure of a recent 
phage therapy clinical trial due to a complex liquid phage drug product suffering 
storage stability issues during the trial is a valuable lesson for the future (Jault et 
al., 2018). Key aspects related to CMAs and CQAs for dry powder phage 
biologicals relevant to spray drying of phage formulations are discussed below. 
The role of excipients in stabilising spray dried bacteriophage drug products 
Spray drying of phage suspensions typically includes excipients in the formulation 
to protect the phages from thermal and desiccation stresses. The critical material 
attributes (CMAs) of excipients used in spray drying needs careful consideration. 
Trehalose, sucrose and lactose have emerged as the most promising excipients 
for spray drying phage suspensions with trehalose being the front runner due to 
its high glass transition temperature and water replacement properties 
(Grasmeijer et al., 2013). Trehalose is the most frequently reported excipient used 
in the spray drying of phages and it has been shown to result in spray dried 
powders with high phage titre and good storage stability (Carrigy et al., 2019; 
Leung et al., 2016, 2017; Matinkhoo et al., 2011; Vandenheuvel et al., 2014). 
Upon spray drying, sugar excipients form amorphous structures with high glass 
transition temperatures (Tg), e.g. in their anhydrous amorphous form Tg of 
trehalose is 115 ˚C and Tg for lactose is 108 ˚C (Chang et al., 2019; Chen et al., 
2000; Roe and Labuza, 2005). Below the glass transition temperature, vitrification 
due to the excipient stabilises the encapsulated bioactive agent and permits 
storage over long periods at ambient or lower temperatures (Carpenter and 
Crowe, 1988; Leung et al., 2017). Trehalose has low toxicity and has been shown 
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al., 2018). Key aspects related to CMAs and CQAs for dry powder phage biologicals relevant to spray 
drying of phage formulations are discussed below. 
Table 1. Typical input material attributes, process parameters and quality attributes of spray dried 
phage powders. 
Input material attributes Process parameters Quality attributes 
• Phage type e.g. 
Myoviridae 
• Intrinsic 
susceptibility of 
phage drug 
candidate to spray 
drying process 
stresses including 
atomisation, drying, 
desiccation, 
osmotic and re-
hydration stresses 
• Excipient type e.g. 
sugars, polymers, 
proteins 
• Solution viscosity 
• Solution solids 
content w/v% 
• Phage titre 
• Lysate purity 
• Drying 
temperature 
• Drying air gas 
flow rate 
• Liquid feed 
flowrate 
• Type of atomiser 
affecting droplet 
size and drying 
rates e.g. two 
fluid nozzle (and 
nozzle size), 
rotary wheel 
(and rotation 
speed). 
• Dryer residence 
time 
• Cyclone 
collection 
efficiency 
(affects yield of 
material) 
• Phage titre in spray dried 
powders (potency) 
• Powder glass transition 
temperature (Tg) 
• Powder moisture content 
• Phage shelf life (Months stored 
under storage specific conditions 
at given temperature and 
relative humidity) 
• Powder re-suspension 
characteristics 
• Powder particle size and size 
distribution 
• Cohesive/adhesive properties 
• Flow properties 
• Bulk/tapped/true density 
• Powder yield 
• Amorphous vs. crystalline 
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Spray drying of phage suspensions typically includes excipients in the formulation to protect the phages 
from thermal and desiccation stresses. The critical material attributes (CMAs) of excipients used in 
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trehalose as an excipient in drying is partly due to its high glass transition temperature at all water 
contents but also because trehalose binds residual water left over from the drying process to form a 
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to protect biological materials including proteins, probiotics and vaccines, against 
desiccation and thermal stress. Crowe et al. (Crowe et al., 1996) suggested that 
the efficacy of trehalose as an excipient in drying is partly due to its high glass 
transition temperature at all water contents but also because trehalose binds 
residual water left over from the drying process to form a dihydrate which might 
otherwise participate in lowering the glass transition temperature to below 
ambient (Vandenheuvel et al., 2014). In the amorphous state, trehalose may 
stabilise protein conformation through hydrogen bonding (Allison et al., 1999). 
Other excipients that have been used to improve the dispersibility of spray dried 
phage containing powders include dextrans, lactose (common excipient used for 
DPI powders), glucose, sucrose, mannitol and, leucine (Leung et al., 2016; 
Matinkhoo et al., 2011; Telko and Hickey, 2005; Vandenheuvel et al., 2013b). 
Sugars such as lactose may be unsuitable excipients for bacteriophages due to 
their reducing properties and hygroscopic nature (Vandenheuvel et al., 2013b). 
Alternatives such as mannitol have been suggested in the literature however, 
mannitol has a tendency to recrystallize rather than remaining amorphous 
(Steckel and Bolzen, 2004). Phage spray drying studies using mannitol have 
reported improved particle dispersion characteristics however, phage viability 
results have been mixed (Leung et al., 2016, 2017). Addition of proteins e.g. 
casein in combination with trehalose have shown good results attributed to 
protection of phages from thermal stress (Matinkhoo et al., 2011). 
Effect of spray drying conditions on phage viability and shelf life 
The spray drying conditions need to be carefully optimised to ensure viability of 
spray dried phages in the final drug product. 2-fluid nozzles typically used for 
atomisation of the phage suspensions for spray drying have been shown to 
generate shear induced damage and loss of phage titre (Leung et al., 2016; 
Vandenheuvel et al., 2013b). Phages are highly sensitive to thermal stresses 
resulting in loss of phage activity at high spray drying temperatures (for co-current 
dryers, outlet temperatures exceeding 60˚C) (Davies and Kelly, 1969; Jończyk et 
al., 2011). Typically, spray drying studies with phages have employed co-current 
dryers operating at low outlet spray drying temperatures (~40-50 ˚C outlet air 
temperatures) resulting in higher phage titres in the powders and reduced overall 
phage losses immediately post spray drying (Leung et al., 2017). High loss of 
phage titres have been observed at higher spray drying temperatures (Leung et 
al., 2016; Matinkhoo et al., 2011; Vandenheuvel et al., 2013b; Walbeck, 2013). 
However, the residual moisture content in the spray dried powders (typically ~5% 
w/w or more, Figure 3) due to low drying temperatures (40-50 ˚C dryer outlet 
temperatures) may result in lowering of the glass transition temperature (Tg) (Roe 
and Labuza, 2005). The glass transition temperature of an amorphous 
pharmaceutical solid is a critical physical property (CQA) which can dramatically 
influence its chemical and physical stability as well as its viscoelastic properties 
(Figure 4). Water acts as a plasticiser in spray dried powders which may also 
adsorb water upon storage due to exposure to a humid atmosphere (Hancock 
and Zografi, 1994). The Tg of amorphous powders such as trehalose, lactose and 
sucrose fall dramatically when the powders contain relatively low amounts of 
moisture due to the plasticization effect of water (Chen et al., 2000; Hancock and 
Zografi, 1994; Roe and Labuza, 2005). Spray dried phage containing powders 
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and Crowe, 1988; Roe and Labuza, 2005) (Figures 5 and 6). The use of excipients that are hygroscopic 
e.g. lactose and trehalose also require careful handling under controlled atmospheric conditions and 
the use of a dry atmosphere controlled glove box is advisable during powder handling to prevent 
exposure of the dry powder to moisture in the atmosphere (Carrigy et al., 2019; Leung et al., 2017; 
Matinkhoo et al., 2011). 
 
Figure 3. Measurement of residual moisture in spray dried powders using thermal gravimetric 
analysis (TGA). Spray dried powder produced at an outlet temperature of 65 oC. 
 Figure 3. Measurement of residual moisture in spray dried powders using thermal gravimetric analysis (TGA). 
Spray dried powder produced at an outlet temperature of 65 oC.
 
Figure 4. Measurement of glass transition temperature using differential scanning calorimetry (DSC) of 
a spray dried powder (using trehalose as excipient). Powder produced at an outlet temperature of 65 oC. 
Onset temperature shown is 45 oC. 
 
Figure 5. Measurement of glass transition temperature using differential scanning calorimetry (DSC) of 
a spray dried powder (using trehalose as excipient). Powder produced at an outlet temperature of 65 oC 
and exposed to storage conditions of 30 oC and 65% relative humidity for 24 hours. Peaks indicate re-
Figure 4. Measurement of glass transition temperature using differential scanning calorimetry (DSC) of a spray 
dried powder (using trehalose as excipient). Powder produced at an outlet temperature of 65 oC. Onset 
temperature shown is 45 oC.
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tend to be amorphous upon production however, storage conditions may subject 
the material to temperatures and humidity conditions lying above the glass 
transition line. Crystallization rates of glasses depend on the storage temperature 
in relation to Tg. Recrystallisation of amorphous sugar in spray dried powders 
negatively affects phage viability perhaps due to denaturing of phage receptor 
proteins as sugar molecules can no longer interact through hydrogen bonding 
with proteins to retain protein conformation upon crystallisation (Carpenter and 
Crowe, 1988; Roe and Labuza, 2005) (Figures 5 and 6). The use of excipients 
that are hygroscopic e.g. lactose and trehalose also require careful handling 
under controlled atmospheric conditions and the use of a dry atmosphere 
controlled glove box is advisable during powder handling to prevent exposure of 
the dry powder to moisture in the atmosphere (Carrigy et al., 2019; Leung et al., 
2017; Matinkhoo et al., 2011). 
Effect of storage conditions on phage stability in spray dried powders 
Storage temperature and relative humidity are the two main factors shown to 
affect phage stability in spray dried powders. Amorphous forms of dry powder 
pharmaceutical biologics are most stable when molecular motion in the 
disordered state is retarded over a meaningful pharmaceutical timeframe 
(Hancock and Zografi, 1994). The storage temperature needs to be considerably 
below the amorphous powder material's Tg to slow down molecular motion such 
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Figure 5. Measurement of glass transition temperature using differential scanning calorimetry (DSC) of a spray 
dried powder (using trehalose as excipient). Powder produced at an outlet temperature of 65 oC and exposed 
to storage conditions of 30 oC and 65% relative humidity for 24 hours. Peaks indicate re-crystallisation of the 
trehalose with endothermic melting peaks for different trehalose polymorphs shown here.
Bacteriophage Encapsulation Malik
that chemical and physical instability of the drug product does not occur over the 
lifetime of the pharmaceutical product, which is typically of the order of a few 
years (Hancock and Zografi, 1994). Storage temperatures 50 oC below the glass 
transition temperature are thought to significantly reduce molecular movement 
and help in lengthening phage powder storage shelf life (Chang et al., 2020; 
Hancock et al., 1995). Refrigerated storage of spray dried powders at relative 
humidity exceeding 20% has been shown to result in loss of phage titre whereas 
samples stored at low humidity were stable (Leung et al., 2017; Vandenheuvel et 
al., 2014). Disaccharides such as trehalose, sucrose and lactose preserve the 
bioactivity of bacteriophages in the dry state. Refrigerated storage of spray dried 
powders was reported to yield higher titres of phage during long term storage 
compared with storage under ambient conditions (Leung et al., 2017). Different 
phage strains formulated and spray dried under identical conditions showed 
!311
crystallisation of the trehalose with endothermic melting peaks for different trehalose polymorphs shown 
here. 
 
 
 
Figure 6. Top Panel: Powder X-ray diffraction results showing amorphous trehalose powders 
immediately, six months and one year following spray drying at 65 oC outlet drying temperature and 
stored at 4 oC (blue curve (immediately after spray drying), green curve (six months after spray drying) 
and red curve (one year after spray drying)). Bottom panel: Same sample exposed to storage conditions 
of 30 oC and 65 % relative humidity for 24 hours resulting in re-crystallisation of the trehalose. 
Effect of storage conditions on phage stability in spray dried powder  
Storage temperature and relative humidity are the two main factors shown to aff ct phage stability in 
spray dried powders. Amorphous forms of dry powder pharmaceutical biologics are most stable when 
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Figure 6. Top Panel: Powder X-ray diffraction results showing amorphous trehalose powders immediately, six 
months and one year following spray drying at 65 oC outlet drying temperature and stored at 4 oC (blue curve 
(immediately after spray drying), green curve (six months after spray drying) and red curve (one year after 
spray drying)). Bottom panel: Same sample exposed to storage conditions of 30 oC and 65 % relative humidity 
for 24 hours resulting in re-crystallisation of the trehalose.
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significant differences in the resulting phage titre suggesting the need for 
individually formulating each phage to be used in a phage cocktail (Vandenheuvel 
et al., 2013b, 2014). The selection of phages as suitable candidates for phage 
therapy should include consideration of whether they lend themselves to spray 
drying i.e. a CMA as part of QbD approach to linking drug product design to the 
QTPP if the final drug product is to be delivered to patients in a stable dry powder 
form. A number of studies have reported spray dried phage powders to have a 
suitable mass median aerosolized diameter for pulmonary delivery of phages to 
treat respiratory infections (Leung et al., 2016; Matinkhoo et al., 2011; 
Vandenheuvel et al., 2013a, 2014). Here the powder particle size is a CQA linking 
powder aerosolization to QTPP. Such critical issues need greater consideration 
early in the product design cycle. 
Conclusions 
Formulation and stability of phage drug products needs greater consideration 
during phage drug product design. Spray drying is a scalable, high throughput 
process, that lends itself to production of stable dry powder phage biologicals. A 
QbD approach to phage drug product design is advocated in this review. CMAs 
include selection of suitable phage candidates at an early stage in drug prodduct 
design that lend themselves to spray drying and using excipients that result in dry 
powders suitable for phage biologicals. A better understanding of the critical 
process parameters related to spray drying and consideration of powder handling, 
packaging and storage conditions is needed. Spray drying of phage biologicals 
can increase stability and shelf life of the drug product as well as incorporating 
targeted delivery and controlled release elements. Spray dried powders can be 
loaded into capsules or made into tablets using direct compression processes 
giving added flexibility for ease of use. 
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